Precigen

Helen Sabzevari, Ph.D., President and CEO

Germantown, MD

(NASDAQ: PGEN)

Virtual Presentation

Precigen is a dedicated discovery and clinical-stage biopharmaceutical company advancing the next-generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated, unique therapies toward clinical proof-of-concept and commercialization.

www.precigen.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions